{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:50:48Z","timestamp":1759614648843,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02769-3","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:17:12Z","timestamp":1747307832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetically engineered K562 cells augment NK cell cytotoxicity against acute myeloid leukemia and reduce dependency on IL-15"],"prefix":"10.1007","volume":"42","author":[{"given":"Saman Sohrabi","family":"Akhkand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina Soufi","family":"Zomorrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. Bmj. 2021;375:n2026.","journal-title":"Bmj"},{"issue":"8","key":"2769_CR2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","volume":"127","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, et al. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127(8):1186\u2013207.","journal-title":"Cancer"},{"issue":"2","key":"2769_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"2769_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:1\u201317.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2769_CR5","first-page":"1770","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance. Am J Cancer Res. 2021;11(4):1770.","journal-title":"Am J Cancer Res"},{"key":"2769_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0612-2","volume":"7","author":"HG Yang","year":"2019","unstructured":"Yang HG, et al. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy. J Immunother Cancer. 2019;7:1\u201317.","journal-title":"J Immunother Cancer"},{"key":"2769_CR7","doi-asserted-by":"publisher","first-page":"125053","DOI":"10.1016\/j.ijpharm.2024.125053","volume":"669","author":"RRS Altaf","year":"2024","unstructured":"Altaf RRS, et al. A review of innovative design strategies: artificial antigen presenting cells in cancer immunotherapy. Int J Pharm. 2024;669:125053.","journal-title":"Int J Pharm"},{"issue":"1","key":"2769_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcyt.2013.08.008","volume":"16","author":"K Tanimoto","year":"2014","unstructured":"Tanimoto K, et al. Genetically engineered fixed K562 cells: potent \u201coff-the-shelf\u201d antigen-presenting cells for generating virus-specific T cells. Cytotherapy. 2014;16(1):135\u201346.","journal-title":"Cytotherapy"},{"issue":"11","key":"2769_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2769_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.4049\/jimmunol.160.4.1831","volume":"160","author":"CS Subauste","year":"1998","unstructured":"Subauste CS, de Waal Malefyt R, Fuh F. Role of CD80 (B7. 1) and CD86 (B7. 2) in the immune response to an intracellular pathogen. J Immunol. 1998;160(4):1831\u201340.","journal-title":"J Immunol"},{"key":"2769_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-319-48066-4_5","volume-title":"Immunotherapy of Melanoma","author":"A Rotte","year":"2016","unstructured":"Rotte A, et al. Overview of Immune System. In: Immunotherapy of Melanoma. Cham: Springer International Publishing; 2016. p. 113\u201342."},{"key":"2769_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-2138-x","volume":"22","author":"P-C Liu","year":"2020","unstructured":"Liu P-C, et al. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells. Arthritis Res Ther. 2020;22:1\u201314.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"2769_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ni1487","volume":"8","author":"ND Huntington","year":"2007","unstructured":"Huntington ND, et al. Interleukin 15\u2013mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol. 2007;8(8):856\u201363.","journal-title":"Nat Immunol"},{"issue":"3","key":"2769_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.micinf.2011.10.006","volume":"14","author":"P-Y Perera","year":"2012","unstructured":"Perera P-Y, et al. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 2012;14(3):247\u201361.","journal-title":"Microbes Infect"},{"issue":"2","key":"2769_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1189\/jlb.0611308","volume":"91","author":"R Wang","year":"2012","unstructured":"Wang R, et al. Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91(2):299\u2013309.","journal-title":"J Leukoc Biol"},{"issue":"10","key":"2769_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 2022;43(10):833\u201347.","journal-title":"Trends Immunol"},{"key":"2769_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3389\/fimmu.2019.00879","volume":"10","author":"S Kweon","year":"2019","unstructured":"Kweon S, et al. Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21. Front Immunol. 2019;10:879.","journal-title":"Front Immunol"},{"issue":"8","key":"2769_CR18","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","volume":"19","author":"Y Liu","year":"2013","unstructured":"Liu Y, et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res. 2013;19(8):2132\u201343.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2769_CR19","doi-asserted-by":"publisher","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","volume":"8","author":"N Shah","year":"2013","unstructured":"Shah N, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013;8(10):e76781.","journal-title":"PLoS One"},{"issue":"2","key":"2769_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0b013e31820d2a21","volume":"34","author":"H Zhang","year":"2011","unstructured":"Zhang H, et al. Activating signals dominate inhibitory signals in CD137L\/IL-15 activated natural killer cells. J Immunother. 2011;34(2):187\u201395.","journal-title":"J. Immunother."},{"issue":"6","key":"2769_CR21","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1158\/1078-0432.CCR-06-1905","volume":"13","author":"MO Butler","year":"2007","unstructured":"Butler MO, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007;13(6):1857\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2769_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00018-024-05412-y","volume":"81","author":"J Li","year":"2024","unstructured":"Li J, Zhou W, Wang W. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells. Cell Mol Life Sci. 2024;81(1):378.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2769_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14653240902807034","volume":"11","author":"M Berg","year":"2009","unstructured":"Berg M, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341\u201355.","journal-title":"Cytotherapy"},{"issue":"9","key":"2769_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/imcb.12679","volume":"101","author":"LJ Dobson","year":"2023","unstructured":"Dobson LJ, et al. Sleeping Beauty kit sets provide rapid and accessible generation of artificial antigen-presenting cells for natural killer cell expansion. Immunol Cell Biol. 2023;101(9):847\u201356.","journal-title":"Immunol Cell Biol"},{"key":"2769_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2012.00402","volume":"3","author":"I Barao","year":"2013","unstructured":"Barao I. The TNF receptor-ligands 4\u20131BB-4-1BBL and GITR-GITRL in NK cell responses. Front Immunol. 2013;3:402.","journal-title":"Front Immunol"},{"issue":"3","key":"2769_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.cgt.7700670","volume":"11","author":"AT Cheuk","year":"2004","unstructured":"Cheuk AT, Mufti GJ, Guinn B-A. Role of 4\u20131BB: 4\u20131BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004;11(3):215\u201326.","journal-title":"Cancer Gene Ther"},{"key":"2769_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10753-014-0082-0","volume":"38","author":"SS Navabi","year":"2015","unstructured":"Navabi SS, et al. Natural killer cell functional activity after 4\u20131BB costimulation. Inflammation. 2015;38:1181\u201390.","journal-title":"Inflammation"},{"key":"2769_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-007-0360-x","volume":"57","author":"D Rudolf","year":"2008","unstructured":"Rudolf D, et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother. 2008;57:175\u201383.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2769_CR29","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Can Res. 2009;69(9):4010\u20137.","journal-title":"Can Res"},{"key":"2769_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela M, et al. Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 2018;422:107\u201317.","journal-title":"Cancer Lett"},{"issue":"12","key":"2769_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083913","volume":"8","author":"Y Peng","year":"2013","unstructured":"Peng Y, et al. CD86 is an activation receptor for NK cell cytotoxicity against tumor cells. PLoS ONE. 2013;8(12): e83913.","journal-title":"PLoS ONE"},{"issue":"8","key":"2769_CR32","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.4049\/jimmunol.168.8.3808","volume":"168","author":"C Costa","year":"2002","unstructured":"Costa C, Barber DF, Fodor WL. Human NK cell-mediated cytotoxicity triggered by CD86 and Gal\u03b1 1, 3-Gal is inhibited in genetically modified porcine cells. J Immunol. 2002;168(8):3808\u201316.","journal-title":"J Immunol"},{"issue":"8","key":"2769_CR33","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.4049\/jimmunol.163.8.4207","volume":"163","author":"JL Wilson","year":"1999","unstructured":"Wilson JL, et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol. 1999;163(8):4207\u201312.","journal-title":"J Immunol"},{"issue":"10","key":"2769_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/imt.11.102","volume":"3","author":"A Malhotra","year":"2011","unstructured":"Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011;3(10):1143\u201366.","journal-title":"Immunotherapy"},{"issue":"2","key":"2769_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt0202-143","volume":"20","author":"MV Maus","year":"2002","unstructured":"Maus MV, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4\u20131BB. Nat Biotechnol. 2002;20(2):143\u20138.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2769_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/mt.sj.6300134","volume":"15","author":"MM Suhoski","year":"2007","unstructured":"Suhoski MM, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15(5):981\u20138.","journal-title":"Mol Ther"},{"issue":"3","key":"2769_CR37","doi-asserted-by":"publisher","first-page":"e96219","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices M, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI insight. 2018;3(3):e96219.","journal-title":"JCI insight"},{"issue":"2","key":"2769_CR38","doi-asserted-by":"publisher","first-page":"e001428","DOI":"10.1136\/jitc-2020-001428","volume":"8","author":"PF Fiore","year":"2020","unstructured":"Fiore PF, et al. Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2):e001428.","journal-title":"J Immunother Cancer"},{"key":"2769_CR39","doi-asserted-by":"publisher","first-page":"436512","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, et al. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:436512.","journal-title":"Front Immunol"},{"issue":"12","key":"2769_CR40","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Journal for immunotherapy of cancer. 2021;9(12):e003894.","journal-title":"Journal for immunotherapy of cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02769-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:16:56Z","timestamp":1748661416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02769-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02769-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no financial interests. The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Tarbiat Modares University, Tehran, Iran (Date 2024.01.06\/No. IR.MODARES.REC.1402.179).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"211"}}